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Catheter ablation of scar-related ventricular tachycardia (VT) often relies on substrate-based approaches
because of hemodynamic instability during VT, multiple VT morphologies, and poor reproducibility of
VT-inducibility, rendering the VT unmappable. As substrate-guided ablation is performed in stable sinus
rhythm, any VT can potentially be targeted regardless of its hemodynamic state. So-called “late
potentials,” conventionally deﬁned as signals detected after the end of QRS, have been traditionally
proposed as ablation targets. However, late potentials cannot be detected in up to 30% of patients with
VT in the setting of ischemic and non-ischemic cardiomyopathy. Recently, a substrate-based approach
that targets poorly coupled ﬁbers surviving within the scar has been developed. These bundles generate
local abnormal ventricular activities (LAVA) and are believed to be responsible for VT. Considering the
limitations of late potential ablation, substrate homogenization with the aim of eliminating all identiﬁed
LAVA appears to be an ideal procedural endpoint. This article reviews substrate-based approaches and
tips for mapping and ablation of VT substrate.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Ventricular tachycardia (VT) most frequently occurs in the
presence of structural heart disease, and it is an important cause
of mortality and morbidity. The vast majority of cases of structural
heat disease are associated with some degree of scarring that
serves as the substrate for sustained VT. Implantable cardioverter
deﬁbrillators (ICDs) or cardiac resynchronization therapy deﬁbril-
lators are used in patients at high risk of sudden death due to
malignant ventricular arrhythmias. However, despite effective VT
termination, recurrent VT, which gives rise to frequent ICD
discharges, is associated with increased rates of mortality and
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congestive heart failure hospitalization as well as reduced patient
quality of life [1–8]. Pharmacological therapies such as beta-
blockers, amiodarone, and sotalol are used to reduce recurrent
VT. The combined use of amiodarone and beta-blockers is more
effective than sotalol or beta-blocker therapy alone [9]. However, it
is important to recognize that these pharmacological therapies
may have adverse effects on clinical outcomes. Amiodarone causes
multiple organ toxicities that are associated with increased mor-
tality in patients with New York Heart Association class III heart
failure and no ICD [10]. The side effects of amiodarone restrict its
long-term use in more than 20% of patients [9].
Catheter ablation is an effective therapeutic option in the
management of scar-related VT [11,12]. Ablation targets a critical
isthmus to interrupt the re-entrant circuit [11–14]. Ideally, VT will
be reliably inducible, hemodynamically well tolerated, and of a
single morphology, allowing for activation and entrainment map-
ping. However, this is the exception rather than the rule. Hemo-
dynamic instability and non-inducibility throughout the
procedure can render the VT unmappable [13,14]. Furthermore,
most patients with scar-related VT have multiple VT circuits with
multiple QRS morphologies on surface electrocardiograms. VT
frequently changes QRS morphology (often with entrainment
attempts). A previous multicenter study showed that 31% of
patients had only unmappable VT and 38% patients had both
mappable and unmappable VT morphologies targeted [13]. In
these situations, a substrate-based approach is attractive. A sub-
strate mapping and ablation strategy in sinus rhythm allows us to
offer ablation therapy to patients with unmappable VT. Various
ablation strategies such as targeting late potentials, endo- and
epicardial scar homogenization, and eliminating local abnormal
ventricular activities (LAVA) have been described previously [15–
23]. In this article, we review substrate-based approaches and tips
for mapping and ablation of VT substrate in patients with struc-
tural heart disease.
2. Substrate mapping in sinus rhythm
In previous studies using explanted human hearts, de Bakker
et al. demonstrated that there are bridges of surviving myocardial
cells within the post-infarction VT scar that connect opposite
borders of the scar [24–26]. The surviving ﬁbers surrounded by
electrically unexcitable ﬁbrosis serve as a slow-conducting path-
way of VT re-entrant circuits. In non-ischemic dilated cardiomyo-
pathy, replacement of muscle by ﬁbrosis creates conducting
channels that similarly facilitate a re-entrant circuit. Cassidy
et al. noted that local electrograms at the sites of VT origin
displayed lower amplitudes and longer electrogram durations
than those at other sites, as obtained from intra-operative map-
ping in sinus rhythm [27]. Endocardial abnormal and fractionated
electrograms can be eradicated by surgical subendocardial resec-
tion, with long-term arrhythmia-free rates of 60–80% in patients
with a previous myocardial infarction [28].
The concept of substrate mapping and ablation evolved from
these surgical experiences. Unlike surgeons who can visually
identify the infarct region, electrophysiologists must locate the
abnormal region using the guidance of local ventricular electro-
grams. Marchlinski et al. reported that voltage mapping in sinus
rhythm using 3-dimensional electroanatomic mapping can char-
acterize electroanatomic substrates [14]. A peak-to-peak bipolar
amplitude o0.5 mV identiﬁes areas with extremely abnormal
signals (dense scars). The dense scar is typically surrounded by a
border zone area with an electrogram amplitude of 0.5–1.5 mV.
This voltage criterion was recently validated by using ﬂuorodeox-
yglucose positron emission tomography [29]. Delayed enhance-
ment as depicted by contrast-enhanced magnetic resonance
imaging can also exhibit a good correlation with the low-voltage
region [30,31].
The surviving myocytes responsible for VT should form anato-
mically deﬁnable conduction channels within the dense background
scar. Arenal et al. and Hsia et al. described that areas of relatively
higher voltage corresponding to surviving bundles of myocardial
cells within the scar tissue can function as conducting channels,
which can be depicted on a color-coded electroanatomic voltage
map [19,32]. They used different voltage cutoff values to deﬁne scars
to identify conducting channels as corridors of continuous electro-
grams in the scar. By applying a stepwise reduction in the deﬁnition
of abnormal voltage from 0.5 to 0.1 mV, most conducting channels
were found to have voltage scar deﬁnitions of r0.2 mV. Recently,
Mountantonakis et al. demonstrated the non-critical relationship
between voltage-deﬁned channels and VT critical isthmuses [33].
Voltage channels can be identiﬁed in 87% of patients with mappable
ischemic VT by adjusting the voltage limits of bipolar maps;
however, the speciﬁcity of those channels in predicting the location
of VT isthmus sites is only 30%. The presence of late potentials inside
the voltage channel signiﬁcantly increases the speciﬁcity for identi-
fying the VT isthmus (Fig. 1). This study indicates the importance of
identifying both abnormal voltage areas and abnormal local electro-
grams as optimal targets of VT substrate ablation.
Because precise assessment of the arrhythmia substrate pre-
and post-ablation is mandatory, substrate-based approaches using
3-dimensional electroanatomic mapping systems are dependent
on high-density mapping of the VT substrate during the baseline
rhythm. Whereas point-by-point mapping can be time consuming
and sometimes operator-dependent, multielectrode mapping may
produce a high-density map in a timely manner. This potentially
overcomes failure due to unreﬁned mapping. High-density elec-
troanatomic mapping is performed with a multipolar mapping
catheter (PentaRay, Biosense Webster, Diamond Bar, CA, USA). The
splines of this catheter are extremely soft and provoke very few
mechanical ectopics. The greatest value of the PentaRay is in
epicardial mapping, as recently described [34]. The elimination of
epicardial arrhythmia substrates from endocardial ablation is
feasible on using the PentaRay catheter. An epicardially placed
PentaRay can be used for both high-density mapping and as a
landmark of the target epicardial abnormal region, precisely
guiding the operator to the facing endocardial site. It also enables
real-time monitoring of the impact of endocardial ablation on
epicardial arrhythmia substrates.
3. Substrate ablation strategies
The presence of surviving bundles of myocytes that were
electrically uncoupled from the surrounding myocardium by
interstitial ﬁbrosis is indicated by abnormal signal characteristics
within low-voltage scars. These abnormal characteristics include
fractionation, prolonged duration, and late potentials [35]. There
are several substrate-based ablation approaches to determine
ablation targets and modify or eliminate the VT substrate.
3.1. Pace mapping
Pace mapping can provide useful information by demonstrating
local tissue excitability, slow condition properties at the pacing site,
and the surface QRS morphology during pacing. Soejima et al.
marked areas with high pacing thresholds of more than 10 mA at a
2-ms pulse width as unexcitable scars [36]. Pacing non-capture may
also indicate insufﬁcient tissue contact by the pacing electrode.
Pace mapping deep within the scar can identify slow conduc-
tion by a long stimulus to the QRS interval (Fig. 2), although a long
stimulus–QRS interval can also occur in bystander regions [37–39].
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The critical isthmus of VT reentry circuits can be traced by pace
mapping. de Chillou et al. reported that pace mapping is useful for
unmasking VT isthmuses in patients with well-tolerated VT in the
post-infarction setting [40].
A good pace map obtained from a scar border region suggests
the approximate location of the VT exit [37,38]. However, a
discrepancy in QRS morphology between VT and the pace map
does not necessarily imply that the region is located far from the VT
reentrant circuit [38]. Pace maps resemble the QRS morphology of
VT at only o30% of likely VT reentry circuit sites that are identiﬁed
using entrainment criteria [38]. This discrepancy may be explained
by multiple exits arising from the scar or functional block during
reentry that is not present during sinus rhythm. Tung et al. recently
described two responses to pace mapping within the scar: multiple
exit sites or pace maps exhibiting 41 morphology and induction of
VT during pace mapping [41]. These functional responses observed
during pace mapping may be speciﬁc for sites critical to reentry.
3.2. Late potentials
“Late potentials” are characterized by low-amplitude (usually
fractionated and o1.5 mV) signals that are detected after the local
Fig. 1. Local ventricular electrograms at critical isthmi during sinus rhythm and ventricular tachycardia (VT). (A) Epicardial voltage map during sinus rhythm (with computed
tomography-derived segmentations of epicardial fat and coronary vessels) displays an area of relatively higher voltage that is ﬂanked by dense scar. Abnormal local
electrograms are detected in the region (arrow). (B) Epicardial isochronal map during VT reveals critical isthmus in the region with fractionated signals covering almost the
entire cycle length of the VT (a, b, c, d).
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ventricular electrogram and QRS. “Isolated delayed potentials” are
usually deﬁned as the second and subsequent electrograms of a
multicomponent potential that are separated from the primary
ventricular electrogram by an isoelectric interval. Late potentials
are considered to originate from slow-conducting surviving bun-
dles of myocardium in areas of ﬁbrotic scar tissue. During pace
mapping, the stimulus–QRS complex was longer at sites at which
late potentials were recorded, which suggests slow conduction at
these sites. Regions with late potentials are more likely to be
components of reentry circuits, as radiofrequency current applica-
tion at those sites more frequently terminated VT than observed at
sites without late potentials [42]. Hsia et al. reported a higher
incidence of late potentials near conducting channels than at the
entrance or exit sites of VT reentrant circuits [43]. Although the
sensitivity of late potentials for identifying critical isthmus during
VT may be reasonably high, their speciﬁcity appears to be poor.
Some sites yielding late potentials during sinus rhythm were
bystander sites during VT and were not in the reentry circuit
despite being sites of slow conduction [44]. Brunckhorst et al.
reported that only 31% of all multipotential electrograms were
located in the vicinity of a VT critical isthmus [45]. Late potential
and multipotential electrograms can also be recorded at the sites
representing ﬁxed conduction block in bystander or so-called
dead-end pathways. Previous reports demonstrated that long
electrogram duration with long stimulus–QRS intervals during
pace mapping improves speciﬁcity [15,20,37,46]. In addition, the
presence of late potentials inside the voltage channel signiﬁcantly
increases the speciﬁcity for identifying the VT isthmus [33].
Fig. 2. Perfect pace map with a long interval from the stimulus to QRS. Epicardial voltage and activation maps during sinus rhythm in patients with arrhythmogenic right
ventricular cardiomyopathy are shown (A and B). There was a delayed fractionated signal at a basal inferior site. Pacing at the site produced a perfect pace-map of the clinical
ventricular tachycardia with an extremely long S-QRS (C and D).
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It is important to recognize that patients with structural heart
disease and scar-related VT often have multiple VT morphologies;
the critical isthmus for one VT reentrant circuit may be a bystander
for another. Moreover, not all VT and future VT morphologies are
inducible or mappable during a procedure. In this regard, a
strategy aiming to eradicate all identiﬁed late potentials arising
from a complex arrhythmia substrate was recently reported by
Vergara et al. [21]. In their report, the value of late potential
elimination was evaluated in 64 patients with VT in the setting of
ischemic and non-ischemic cardiomyopathy. After a 13-month
follow-up period, VT recurrence occurred in 9.5% of patients who
underwent abolition of late potentials and in 75% of those with
incomplete abolition [Po0.0001].
The impact of ablation targeting late potentials on clinical
outcome in non-ischemic dilated cardiomyopathy has been also
reported. Kuhne et al. demonstrated that the presence of late
potentials was predictive of a better outcome following an ablation
procedure in patients with non-ischemic dilated cardiomyopathy
[47]. However, the efﬁcacy of late potential ablation appears to be
limited. Nakahara et al. described that an ablation strategy target-
ing late potentials was more effective in patients with ischemic
cardiomyopathy than in those with non-ischemic cardiomyopathy
[48].
Nogami et al. reported that in patients with arrhythmogenic
right ventricular cardiomyopathy (ARVC), ablation and elimination
of delayed potentials were associated with a lower VT recurrence
than no or unchanged delayed potentials [49].
3.3. Limitation of late potential mapping
Although ablation strategies targeting late potentials with
the application of an arbitrary cutoff such as the end of the
surface QRS appear simple and reasonable, they encounter a
limitation that should be recognized during the mapping and
ablation of VT substrates. Late potentials may be more likely to
occur in late-activating regions of the ventricle such as the basal
inferior region of the left ventricle in inferior infarction, the
basal perivalvular scars in non-ischemic cardiomyopathy, or the
right ventricular perivalvular region in ARVC. In contrast, late
potentials may be less likely to occur in an area that is activated
early such as the left ventricular septum.
In theory, the left ventricular area ﬁrst excited in sinus rhythm
is the endocardial septum below the attachment of the mitral
valve [50]. The wave of excitation spreads from the endocardium
to the epicardium. The epicardial basal posterior region is the last
region to be activated [50]. This limitation of late potential
mapping is discussed in a recent report in which the lateness of
LAVA was determined largely by the scar localization as well as
poor conduction at the edge of and within the scar [51]. It is
intuitive that, given 2 scars of identical electrical properties, the
scar stimulated later by an activation front would possess a higher
proportion of late signals. Therefore, late abnormal potentials
would be more likely to occur in late-activating regions of the
ventricle and vice versa. In a prior report, the lateness of abnormal
electrograms correlated well with the timing of the electrogram
onset (Fig. 3). Consequently, the chance of detecting late potentials
increases when the electrogram onset is later. It is not surprising
that the majority of abnormal epicardial electrograms are detected
after the QRS complex. By contrast, delayed potentials are less
likely to be found in the endocardial septum, which is activated at
least 30 ms earlier than in the basal lateral region. These ﬁndings
are in line with a previous study demonstrating the underrepre-
sentation of late potentials as assessed by signal-averaged electro-
grams in anteroseptal infarction compared with the ﬁndings in
inferior and/or lateral infarction, which might be explained by the
different timing of the electrogram onset [52].
Although so-called “late potentials” have been proposed as
targets of substrate-based ablation, they could not be found in
3–29% of patients with VT due to ischemic and non-ischemic
cardiomyopathy in previous studies [21,42,48,53]. In a prior report
Fig. 3. Correlation between the timing of electrogram onset and lateness of local abnormal ventricular activity (LAVA). There was a signiﬁcant positive correlation between
the interval from the onset of the QRS complex to the ventricular electrogram (EGM onset) and the interval from the surface QRS onset to the end of LAVA (LAVA lateness)
(r¼0.52, Po0.001). Therefore, the chance of detecting late LAVA increases when the electrogram onset is later.
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from the Bordeaux group that assessed the characteristics of
LAVAs in relation to their anatomical location, 10% of patients
displayed LAVA that were buried within the QRS and that would
not have been identiﬁed using the previous deﬁnitions [51].
Furthermore, almost half of all endocardial septal LAVAs did not
extend beyond the end of the QRS complex and fell short of “late
potential” criteria.
Although extremely delayed abnormal signals can improve the
speciﬁcity of the prediction of critical isthmus of VT, critical sites
for VT perpetuation may not necessarily display late potentials.
Harada et al. described that late potentials during sinus rhythm
were absent in 29% of central VT reentry circuits and 46% of VT
termination sites [42]. It is plausible that substrate-based ablation
strategies that only target “late potentials” may miss critical
arrhythmogenic substrates, particularly in the septum and other
early-to-activate regions. In these situations, ventricular pacing
maneuvers may be frequently required to decouple the non-
delayed abnormal ventricular potentials from the far-ﬁeld ventri-
cular potential.
3.4. LAVA
The substrate ablation approach with the procedural endpoint
of LAVA elimination was recently reported by Jaïs et al. LAVA are
generated by poorly coupled viable ﬁbers within the scar [23].
They may appear at any time during or after the far-ﬁeld
ventricular electrogram in sinus rhythm; that is, LAVA may be
separated from the far-ﬁeld signal by an isoelectric line and extend
beyond the end of the surface QRS, but they may also appear to be
fused or buried within the QRS. LAVA during sinus rhythm were
deﬁned by electrograms with the following features: (i) sharp,
high-frequency ventricular potentials distinct from the far-ﬁeld
ventricular electrogram, (ii) occurring anytime during or (most
frequently) after the far-ﬁeld ventricular electrogram during
sinus rhythm, and (iii) occasionally displaying double or multiple
high-frequency signals separated by extremely low-amplitude
signals or an isoelectric interval. The concept for conﬁrming the
nature of these LAVA and distinguishing them from far-ﬁeld
potentials is to demonstrate their poorly coupled nature to the
rest of the myocardium. For this purpose, ventricular pacing
maneuvers are performed when LAVA are thought to be fused
with the far-ﬁeld ventricular potential. RV pacing occasionally
unmasked LAVAs that were not obvious during sinus rhythm
(Fig. 4). Programmed stimulation could increase the delay of
LAVAs from far-ﬁeld ventricular potential based on the conduction
properties of LAVA; i.e., they usually are poorly coupled to the rest
of the myocardium [23,51]. During a local ectopic, LAVA may
become clear because these signals are composed of sharp near-
ﬁeld activities that are distinct from the far-ﬁeld ventricular signal
(Fig. 5). Evidence that LAVA represent local near-ﬁeld activation
signals at the site of the recording electrode, whereas the initial
dull potential represents far-ﬁeld signal, is supported by the
disappearance of LAVA after ablation without a change in the
morphology of the far-ﬁeld potential (Fig. 6).
LAVA are found in more than 95% of patients with scar-related VT
[23]. They are frequently assimilated to potentials occurring after the
surface QRS, producing what have traditionally been deﬁned as “late
potentials.” However, some of these LAVA potentials appear to be
fused with the far-ﬁeld ventricular potentials, and they would not be
identiﬁed using these deﬁnitions. Nonetheless, they may represent
channels that may support VT. If the abnormal potentials have an
activation sequence from the edge to the center of the scar during
sinus rhythm, ablation targeting the earliest signals at the edge of the
scar should be performed. This approach is based on a previous
Fig. 4. Local abnormal ventricular activity (LAVA) unmasked during pacing rhythm. The local ventricular electrogram in sinus rhythm (arrow) apparently consisted of a
single, high-amplitude signal. However, fractionated components were possibly fused with the single potential. Pacing from the right ventricle markedly changed the signal
characteristics and unmasked LAVAs (arrowhead) from the far-ﬁeld signal (dotted arrow).
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report in which the conducting channels of VT reentrant circuit were
considered to have interconnecting pathways with orthodromic
activation from the edge to the inner region of the scar [19]. This
approach aims to disconnect the entire slow-conducting channel by
using fewer radiofrequency deliveries as compared to a strategy
targeting all late potentials and thus the entire channel [23,51,54].
Fig. 5. Local abnormal ventricular activity (LAVA) unmasked during premature ventricular contraction. LAVA that was fused with far-ﬁeld ventricular potential was recorded
during sinus rhythm (SR) at the inferior wall in a patient with inferior post-infarction. LAVA (*) was unmasked during a premature ventricular contraction (PVC).
Fig. 6. Ablation of local abnormal ventricular activity (LAVA). LAVA fused with the far-ﬁeld ventricular potential (arrow) was recorded before ablation. After radiofrequency
ablation, LAVA was abolished, whereas the far-ﬁeld potential remained (dotted arrow).
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Jaïs et al. reported that complete elimination of LAVA was
associated with superior survival free from recurrent VT during
long-term follow-up. Complete elimination of LAVA was associated
with a signiﬁcant reduction in recurrent ventricular tachycardia
(hazard ratio¼0.49; 95% conﬁdence interval¼0.26–0.95; Po0.035).
3.5. Endocardial and epicardial scar homogenization
Scar homogenization as described by Di Biase et al. targets the
entire scar, with a particular focus on late fractioned signals in scar
tissue [22]. This strategy targets the entire scar and all endocardial
and epicardial signals persisting longer than 70 ms or displaying
4 or more deﬂections or an amplitude less than 1.5 mV. This novel
ablation technique was associated with excellent VT-free survival
rate. However, it may lead to the most extensive ablation and was
reported to have an ablation time of 74721 min, considerably
longer than the 26711 min required for the LAVA elimination
strategy in the report of Jaïs et al. In patients who underwent scar
homogenization, despite extensive ablation including an epicardial
approach in half of the patients, there were no periprocedural
complications. In addition, it is surprising that scar homogeniza-
tion achieved 100% non-inducibility of any ventricular arrhythmia.
The participating institutions possess signiﬁcant experience in
complex endo- and epicardial ablation procedures. Extrapolating
their results to other institutions may need to be done carefully.
4. Epicardial mapping and ablation
Since the ﬁrst description of epicardial VT ablation with percuta-
neous subxiphoid access in 1996, epicardial mapping and ablation
have been widely performed for the treatment of scar-related VT
Fig. 7. Successful endocardial ablation of epicardial local abnormal ventricular activity (LAVA). The multielectrode catheter (PentaRay Nav) lying epicardially displayed
delayed LAVA. Endocardial ablation at the site facing the epicardial PentaRay Nav eliminated epicardial LAVA after increasing its delay.
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[55]. Svenson et al. reported that epicardial VT circuits are particu-
larly common in patients after inferior wall infarction [56]. In 14
patients with post-infarction of the inferior wall, 7 of 30 VTs had a
reentry circuit identiﬁed and ablated from the epicardium [57]. In
patients with stable post-infarction VT, the critical isthmus was
considered to be located epicardially in approximately 10–15% of
patients [57,58]. Soejima et al. reported that a prior surgical proce-
dure in post-infarction patients poses a technical challenge to
percutaneous epicardial access in the electrophysiology laboratory
due to pericardial adhesions that can be overcome by limited direct
subxiphoid surgical approaches [59].
In patients with non-ischemic dilated cardiomyopathy, the
epicardial VT substrate is more frequently identiﬁed, and com-
bined endocardial and epicardial ablation has been used to achieve
better outcomes [60–62]. However, Nakahara et al. reported that
success rate of VT ablation in non-ischemic cardiomyopathy
appears to be worse than that in ischemic cardiomyopathy [48].
Tung et al. demonstrated no signiﬁcant difference in VT-free
survival in patients with non-ischemic cardiomyopathy who
underwent a combined endo- and epicardial approach compared
with those who underwent endo-only ablation (36% versus 33%)
[63]. Patients with non-ischemic cardiomyopathy remain at high
risk for recurrent VT despite epicardial ablation.
In patients with ARVC, the VT substrate is predominantly
distributed on the epicardium, as the pathological hallmark of
ARVC, ﬁbrofatty replacement of the right ventricle, starts from the
epicardium and proceeds to the endocardium [64–67]. Therefore,
combined endocardial and epicardial ablation yields higher long-
term control of ventricular tachycardia off antiarrhythmic therapy
than endocardial ablation alone [67–69].
There are potential risks associated with epicardial ablation,
such as pericardial bleeding and injury of coronary vessels or the
phrenic nerve [70–72]. Della Bella et al. reported a 4.1% rate of
major complications in 218 patients in 6 European centers [71].
Sacher et al. reported a complication rate of 7% for 156 epicardial
procedures at 3 institutions [72]. In a recent experimental study by
Sacher et al., contact force not directed toward the heart resulted
in pulmonary lesions [73]. A recent report from the Bordeaux
group provided important information and insight on the issues of
epicardial ablation [34]. Successful elimination of epicardial LAVA
using endocardial ablation is feasible and most likely to be
successful in patients with ARVC and ischemic cardiomyopathy
in whom the epicardial substrate is located in a thin myocardial
wall (Fig. 7). The data provide important clinical implications,
raising the possibility that endocardial ablation can be useful in
some circumstances in which epicardial ablation may be limited
by the proximity to coronary vessels or the phrenic nerve.
Furthermore, a subset of epicardial LAVA disappeared after com-
plete elimination of endocardial LAVA. These data suggest that
endocardial ablation could be performed ﬁrst during substrate
ablation procedures to reduce or obviate the need for epicardial
ablation.
5. Endpoint of substrate ablation
Although some studies demonstrated that acute VT ablation
success as deﬁned by non-inducibility of VT following ablation was
associated with reduced cardiac mortality [74–78], this has not
been a consistent ﬁnding. Whereas the inducibility of any VT is a
poor prognostic sign, the absence of inducibility does not mean VT
will not recur [13,79,80]. A VT stimulation protocol may lack
reproducibility and may be unable to induce the target VTs at
the beginning of procedure despite clinical documentation [1,81].
The degree of sedation, the intensity of the induction protocol, and
the pacing site (from the right ventricular apex, left ventricle, or
within the scar) may all affect the result of an inducibility test. In
the instance in which the patient is non-inducible at the start of
the procedure, the value of this particular endpoint is uncertain.
Furthermore, whether the goal should be non-inducibility of any
VT or whether the absence of clinical VT but persistent inducibility
of non-clinical VT is reasonable is the subject of ongoing
controversy.
Jaïs et al. reported that complete LAVA elimination is a better
predictor of success than the absence of inducibility [23]. Achiev-
ing complete elimination of LAVA yields superior survival free
from recurrent VT during long-term follow-up. Scar homogeniza-
tion signiﬁcantly increases the freedom from VT recurrence [22].
These ablation strategies aim to abolish all potential VT channels
occurring from complex arrhythmia substrate and, importantly, do
not rely on VT inducibility as a procedural endpoint. However,
these studies were not randomized. Further randomized trials
with prospective data collection from larger samples are war-
ranted to evaluate the beneﬁts of complete substrate modiﬁcation
in terms of clinical outcome.
6. Summary
The safety and efﬁcacy of ablation therapy for scar-related VT
have been enhanced by improvements in the understanding of the
pathophysiology of VT as well as the development of catheter
ablation techniques. As substrate-guided ablation is performed in
stable sinus rhythm, any VT may be targeted regardless of its
hemodynamic state. Substrate modiﬁcation strategies aiming to
eradicate all potential reentrant circuits are associated with better
prognosis, probably because of the following reasons: patients
often have multiple VT morphologies, the critical isthmus for one
VT may be a bystander for another, and not all VT and future VT
morphologies are inducible or mappable during a procedure.
Therefore, substrate homogenization strategies that target all
identiﬁed abnormal local electrograms as well as “late potential”
are reasonable. Previous studies have demonstrated various abla-
tion techniques including detailed pace mapping to identify VT
critical isthmus, ablation of early-coupled abnormal electrograms
to disconnect slow-conducting channels of VT reentrant circuits,
and epicardial substrate modiﬁcation from endocardial ablation.
Further randomized prospective studies are warranted to assess
whether the substrate modiﬁcation using these techniques has a
prognostic beneﬁt.
Conﬂict of interest
None.
Acknowledgments
The author would like to thank Matthew Daly for help in the
preparation of this manuscript.
References
[1] Paciﬁco A, Ferlic LL, Cedillo-Salazar FR, et al. Shocks as predictors of survival in
patients with implantable cardioverter-deﬁbrillators. J Am Coll Cardiol
1999;34:204–10.
[2] Bänsch D, Böcker D, Brunn J, et al. Clusters of ventricular tachycardias signify
impaired survival in patients with idiopathic dilated cardiomyopathy and
implantable cardioverter deﬁbrillators. J Am Coll Cardiol 2000;36:566–73.
[3] Mitchell LB, Pineda A, Titus JL, et al. Sudden death in patients with
implantable cardioverter deﬁbrillators: the importance of post-shock electro-
mechanical dissociation. J Am Coll Cardiol 2002;39:1323–8.
[4] Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of deﬁbrillator
shocks in patients with heart failure. N Engl J Med 2008;359:1009–17.
Y. Komatsu / Journal of Arrhythmia 30 (2014) 272–282280
[5] Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients
after termination of ventricular tachyarrhythmia by an implanted deﬁbrillator.
Circulation 2004;110:3760–5.
[6] Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia storms in
postinfarction patients with implantable deﬁbrillators for primary prevention
indications: a MADIT-II substudy. Heart Rhythm 2007;4:1395–402.
[7] Larsen GK, Evans J, Lambert WE, et al. Shocks burden and increased mortality
in implantable cardioverter-deﬁbrillator patients. Heart Rhythm 2011;8:
1881–6.
[8] Sears SF, Hauf JD, Kirian K, et al. Posttraumatic stress and the implantable
cardioverter-deﬁbrillator patient: what the electrophysiologist needs to know.
Circ Arrhythm Electrophysiol 2011;4:242–50.
[9] Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers,
amiodarone plus beta-blockers or sotalol for prevention of shocks from
implantable cardioverter deﬁbrillators: the OPTIC study: a randomized trial.
J Am Med Assoc 2006;295:165–71.
[10] Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-
deﬁbrillator, amiodarone, and placebo on the mode of death in stable patients
with heart failure: analysis from the sudden cardiac death in heart failure trial.
Circulation 2009;120:2170–6.
[11] Stevenson WG, Khan H, Sager P, et al. Identiﬁcation of reentry circuit sites
during catheter mapping and radiofrequency ablation of ventricular tachy-
cardia late after myocardial infarction. Circulation 1993;88:1647–70.
[12] Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the
prevention of deﬁbrillator therapy. N Engl J Med 2007;357:2657–65.
[13] Stevenson WG, Wilber DJ, Natale A, et al. Multicenter Thermocool VT Ablation
Trial Investigators. Irrigated radiofrequency catheter ablation guided by
electroanatomic mapping for recurrent ventricular tachycardia after myocar-
dial infarction: the multicenter thermocool ventricular tachycardia ablation
trial. Circulation 2008;118:2773–82.
[14] Marchlinski FE, Callans DJ, Gottlieb CD, et al. Linear ablation lesions for control
of unmappable ventricular tachycardia in patients with ischemic and non-
ischemic cardiomyopathy. Circulation 2000;101:1288–96.
[15] Bogun F, Good E, Reich S, et al. Isolated potentials during sinus rhythm and
pace-mapping within scars as guides for ablation of post-infarction ventricular
tachycardia. J Am Coll Cardiol 2006;47:2013–9.
[16] Cesario DA, Vaseghi M, Boyle NG, et al. Value of high-density endocardial and
epicardial mapping for catheter ablation of hemodynamically unstable ven-
tricular tachycardia. Heart Rhythm 2006;3:1–10.
[17] Deneke T, Grewe PH, Lawo T, et al. Substrate-modiﬁcation using electro-
anatomical mapping in sinus rhythm to treat ventricular tachycardia in
patients with ischemic cardiomyopathy. Z Kardiol 2005;94:453–60.
[18] Haqqani HM, Marchlinski FE. Electrophysiologic substrate underlying post-
infarction ventricular tachycardia: characterization and role in catheter abla-
tion. Heart Rhythm 2009;6:S70–6.
[19] Arenal A, del Castillo S, Gonzalez-Torrecilla E, et al. Tachycardia-related
channel in the scar tissue in patients with sustained monomorphic ventricular
tachycardias: inﬂuence of the voltage scar deﬁnition. Circulation
2004;110:2568–74.
[20] Arenal Á, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an
isolated, delayed component as treatment of unmappable monomorphic
ventricular tachycardias in patients with structural heart disease. J Am Coll
Cardiol 2003;41:81–92.
[21] Vergara P, Trevisi N, Ricco A, et al. Late potentials abolition as an additional
technique for reduction of arrhythmia recurrence in scar related ventricular
tachycardia ablation. J Cardiovasc Electrophysiol 2012;23:621–7.
[22] Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization
of the scar versus limited substrate ablation for the treatment of electrical
storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol
2012;60:132–41.
[23] Jaïs P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular
activities: a new end point for substrate modiﬁcation in patients with scar-
related ventricular tachycardia. Circulation 2012;125:2184–96.
[24] de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the
infarcted, Langendorff-perfused human heart: role of the arrangement of
surviving cardiac ﬁbers. J Am Coll Cardiol 1990;15:1594–607.
[25] de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular
tachycardia in patients with chronic ischemic heart disease: electrophysiolo-
gic and anatomic correlation. Circulation 1988;77:589–606.
[26] de Bakker JM, van Capelle FJ, Janse MJ, et al. Macroreentry in the infarcted
human heart: the mechanism of ventricular tachycardias with a “focal”
activation pattern. J Am Coll Cardiol 1991;18:1005–14.
[27] Cassidy DM, Vassallo JA, Buxton AE, et al. The value of catheter mapping
during sinus rhythm to localize site of origin of ventricular tachycardia.
Circulation 1984;69:1103–10.
[28] Miller JM, Tyson GS, Hargrove WC, et al. Effect of subendocardial resection on
sinus rhythm endocardial electrogram abnormalities. Circulation
1995;92:2385–91.
[29] Kettering K, Weig HJ, Reimold M, et al. Catheter ablation of ventricular
tachycardias in patients with ischemic cardiomyopathy: validation of voltage
mapping criteria for substrate modiﬁcation by myocardial viability assessment
using FDG PET. Clin Res Cardiol 2010;99:753–60.
[30] Desjardins B, Crawford T, Good E, et al. Infarct architecture and characteristics
on delayed enhanced magnetic resonance imaging and electroanatomic
mapping in patients with postinfarction ventricular arrhythmia. Heart Rhythm
2009;6:644–51.
[31] Wijnmaalen AP, van der Geest RJ, van Huls van Taxis CF, et al. Head-to-head
comparison of contrast-enhanced magnetic resonance imaging and electro-
anatomical voltage mapping to assess post-infarct scar characteristics in
patients with ventricular tachycardias: real-time image integration and
reversed registration. Eur Heart J 2011;32:104–14.
[32] Hsia HH, Lin D, Sauer WH, et al. Anatomic characterization of endocardial
substrate for hemodynamically stable reentrant ventricular tachycardia: identi-
ﬁcation of endocardial conducting channels. Heart Rhythm 2006;3:503–12.
[33] Mountantonakis SE, Park RE, Frankel DS, et al. Relationship between voltage
map “channels” and the location of critical isthmus sites in patients with post-
infarction cardiomyopathy and ventricular tachycardia. J Am Coll Cardiol
2013;61:2088–95.
[34] Komatsu Y, Daly M, Sacher F, et al. Endocardial ablation to eliminate
epicardial arrhythmia substrate in scar-related ventricular tachycardia. J Am
Coll Cardiol 2014;63:1416–26.
[35] Gardner PI, Ursell PC, Fenoglio Jr. JJ, et al. Electrophysiologic and anatomic
basis for fractionated electrograms recorded from healed myocardial infarcts.
Circulation 1985;72:596–611.
[36] Soejima K, Stevenson WG, Maisel WH, et al. Electrically unexcitable scar
mapping based on pacing threshold for identiﬁcation of the reentry circuit
isthmus: feasibility for guiding ventricular tachycardia ablation. Circulation
2002;106:1678–83.
[37] Brunckhorst CB, Delacretaz E, Soejima K, et al. Identiﬁcation of the ventricular
tachycardia isthmus after infarction by pace mapping. Circulation
2004;110:652–9.
[38] Stevenson WG, Sager PT, Natterson PD, et al. Relation of pace mapping QRS
conﬁguration and conduction delay to ventricular tachycardia reentry circuits
in human infarct scars. J Am Coll Cardiol 1995;26:481–8.
[39] Brunckhorst CB, Stevenson WG, Soejima K, et al. Relationship of slow
conduction detected by pace-mapping to ventricular tachycardia re-entry
circuit sites after infarction. J Am Coll Cardiol 2003;41:802–9.
[40] de Chillou C, Groben L, Magnin-Poull I, et al. Localizing the critical isthmus of
post-infarct ventricular tachycardia: the value of pace mapping during sinus
rhythm. Heart Rhythm 2014;11:175–81.
[41] Tung R, Mathuria N, Michowitz Y, et al. Functional pace-mapping responses
for identiﬁcation of targets for catheter ablation of scar-mediated ventricular
tachycardia. Circ Arrhythm Electrophysiol 2012;5:264–72.
[42] Harada T, Stevenson WG, Kocovic DZ, et al. Catheter ablation of ventricular
tachycardia after myocardial infarction: relation to endocardial sinus rhythm
late potentials to the reentry circuit. J Am Coll Cardiol 1997;30:1015–23.
[43] Hsia HH, Lin D, Sauer WH, et al. Relationship of late potentials to the
ventricular circuit deﬁned by entrainment. J Interv Card Electrophysiol
2009;26:21–9.
[44] Hood MA, Pogwizd SM, Peirick J, et al. Contribution of myocardium
responsible for ventricular tachycardia to abnormalities detected by analysis
of signal-averaged ECGs. Circulation 1992;86:1888–901.
[45] Brunckhorst CB, Stevenson WG, Jackman WM, et al. Ventricular mapping
during atrial and ventricular pacing. Relationship of multipotential electro-
grams to ventricular tachycardia reentry circuits after myocardial infarction.
Eur Heart J 2002;23:1131–8.
[46] Bogun F, Bahu M, Knight BP, et al. Response to pacing at sites of isolated
diastolic potentials during ventricular tachycardia in patients with previous
myocardial infarction. J Am Coll Cardiol 1997;30:505–13.
[47] Kuhne M, Abrams G, Sarrazin JF, et al. Isolated potentials and pace-mapping
as guides for ablation of ventricular tachycardia in various types of nonis-
chemic cardiomyopathy. J Cardiovasc Electrophysiol 2010;21:1017–23.
[48] Nakahara S, Tung R, Ramirez RJ, et al. Characterization of the arrhythmogenic
substrate in ischemic and nonischemic cardiomyopathy implications for
catheter ablation of hemodynamically unstable ventricular tachycardia. J Am
Coll Cardiol 2010;55:2355–65.
[49] Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated delayed
component as an endpoint of catheter ablation in arrhythmogenic right
ventricular cardiomyopathy: predictor for long-term success. J Cardiovasc
Electrophysiol 2008;19:681–8.
[50] Durrer D, van Dam RT, Freud GE, et al. Total excitation of the isolated human
heart. Circulation 1970;41:899–912.
[51] Komatsu Y, Daly M, Sacher F, et al. Electrophysiologic characterization of local
abnormal ventricular activities in post-infarction ventricular tachycardia with
respect to their anatomical location. Heart Rhythm 2013;10:1630–7.
[52] Benchimol-Barbosa PR, Muniz RT. Ventricular late potential duration corre-
lates to the time of onset of electrical transients during ventricular activation
in subjects post-acute myocardial infarction. Int J Cardiol 2008;129:285–7.
[53] Arenal Á, Hernández J, Calvo D, et al. Safety, long-term results, and predictors
of recurrence after complete endocardial ventricular tachycardia substrate
ablation in patients with previous myocardial infarction. Am J Cardiol
2013;111:499–505.
[54] Tung R, Mathuria NS, Nagel R, et al. Impact of local ablation on interconnected
channels within ventricular scar: mechanistic implications for substrate
modiﬁcation. Circ Arrhythm Electrophysiol 2013;6:1131–8.
[55] Sosa E, Scanavacca M, d'Avila A, et al. A new technique to perform epicardial
mapping in the electrophysiology laboratory. J Cardiovasc Electrophysiol
1996;7:531–6.
[56] Svenson RH, Littmann L, Gallagher JJ, et al. Termination of ventricular
tachycardia with epicardial laser photocoagulation: a clinical comparison with
patients undergoing successful endocardial photocoagulation alone. J Am Coll
Cardiol 1990;15:163–70.
Y. Komatsu / Journal of Arrhythmia 30 (2014) 272–282 281
[57] Sosa E, Scanavacca M, d'Avila A, et al. Nonsurgical transthoracic epicardial
catheter ablation to treat recurrent ventricular tachycardia occurring late after
myocardial infarction. J Am Coll Cardiol 2000;35:1442–9.
[58] Verma A, Marrouche NF, Schweikert RA, et al. Relationship between
successful ablation sites and the scar border zone deﬁned by substrate
mapping for ventricular tachycardia post-myocardial infarction. J Cardiovasc
Electrophysiol 2005;16:465–71.
[59] Soejima K, Couper G, Cooper JM, et al. Subxiphoid surgical approach for
epicardial catheter-based mapping and ablation in patients with prior cardiac
surgery or difﬁcult pericardial access. Circulation 2004;110:1197–201.
[60] Soejima K, Stevenson WG, Sapp JL, et al. Endocardial and epicardial radio-
frequency ablation of ventricular tachycardia associated with dilated cardio-
myopathy. J Am Coll Cardiol 2004;43:1834–42.
[61] Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate and ablation
outcome for suspected epicardial ventricular tachycardia in left ventricular
nonischemic cardiomyopathy. J Am Coll Cardiol 2009;54:799–808.
[62] Maury P, Escourrou G, Guilbeau C, et al. Histopathologic effects of endocardial
and epicardial percutaneous radio-frequency catheter ablation in dilated
nonischemic cardiomyopathy. Pacing Clin Electrophysiol 2008;31:1218–22.
[63] Tung R, Michowitz Y, Yu R, et al. Epicardial ablation of ventricular
tachycardia: an institutional experience of safety and efﬁcacy. Heart Rhythm
2013;10:490–8.
[64] Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular
cardiomyopathy. Lancet 2009;373:1289–300.
[65] Fontaine G, Fontaliran F, Hébert JL, et al. Arrhythmogenic right ventricular
dysplasia. Annu Rev Med 1999;50:17–35.
[66] Basso C, Thiene G, Corrado D, et al. Arrhythmogenic right ventricular
cardiomyopathy: dysplasia, dystrophy, or myocarditis? Circulation
1996;94:983–91.
[67] Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and outcome with
epicardial ablation of ventricular tachycardia in arrhythmogenic right ven-
tricular cardiomyopathy/dysplasia. Circulation 2009;120:366–75.
[68] Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in
arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free
survival after endo-epicardial substrate based mapping and ablation. Circ
Arrhythm Electrophysiol 2011;4:478–85.
[69] Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of
ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardio-
myopathy. Circ Arrhythm Electrophysiol 2012;5:499–505.
[70] Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert
consensus on catheter ablation of ventricular arrhythmias: developed in a
partnership with the European Heart Rhythm Association (EHRA), a registered
branch of the European Society of Cardiology (ESC), and the Heart Rhythm
Society (HRS); in collaboration with the American College of Cardiology (ACC)
and the American Heart Association (AHA). Heart Rhythm 2009;6:886–993.
[71] Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular
tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol
2011;4:653–9.
[72] Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachy-
cardia ablation a multicenter safety study. J Am Coll Cardiol 2010;55:2366–72.
[73] Sacher F, Wright M, Derval N, et al. Endocardial versus epicardial ventricular
radiofrequency ablation: utility of in vivo contact force assessment. Circ
Arrhythm Electrophysiol 2013;6:144–50.
[74] Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the
treatment of electrical storm in patients with implantable cardioverter-
deﬁbrillators: short- and long-term outcomes in a prospective single-center
study. Circulation 2008;117:462–9.
[75] Sauer WH, Zado E, Gerstenfeld EP, et al. Incidence and predictors of mortality
following ablation of ventricular tachycardia in patients with an implantable
cardioverter-deﬁbrillator. Heart Rhythm 2010;7:9–14.
[76] Della Bella P, Barratto F, Tsiachris D, et al. Management of ventricular
tachycardia in the setting of a dedicated unit for the treatment of complex
ventricular arrhythmias: long-term outcome after ablation. Circulation
2013;127:1359–68.
[77] Tokuda M, Kojodjojo P, Tung S, et al. Acute failure of catheter ablation for
ventricular tachycardia due to structural heart disease: causes and signiﬁ-
cance. J Am Heart Assoc 2013;2:e000072, http://dx.doi.org/10.1161/
JAHA.113.000072.
[78] Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of
ventricular tachycardia in dilated non-ischemic cardiomyopathy in compar-
ison to ischemic cardiomyopathy: results from the prospective HEart Centre of
LeiPzig VT (HELP – VT) Study. Circulation 2014;129:728–36.
[79] Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular
tachycardia in patients with structural heart disease using cooled radio-
frequency energy: results of a prospective multicenter study. Cooled RF Multi
Center Investigators Group. J Am Coll Cardiol 2000;35:1905–14.
[80] Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-
related ventricular tachycardia using electroanatomical mapping and irrigated
ablation technology: results of the prospective multicenter Euro-VT-study. J
Cardiovasc Electrophysiol 2010;21:47–53.
[81] Rosenbaum MS, Wilber DJ, Finkelstein D, et al. Immediate Reproducibility of
electrically induced sustained monomorphic ventricular tachycardia before
and during antiarrhythmic therapy. J Am Coll Cardiol 1991;17:133–8.
Y. Komatsu / Journal of Arrhythmia 30 (2014) 272–282282
